AMINOTHIOL THERAPY IN NEPHROPATHIC CYSTINOSIS

氨基硫醇治疗肾病性胱氨酸贮积症

• 批准号: 6244626
• 负责人: JESS G THOENE
• 金额: $ 2.22万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-02-20 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6244626
• 关键词: child (0-11); clinical research; clinical trials; cysteamine; cystinosis; drug metabolism; drug screening /evaluation; human subject; human therapy evaluation; kidney disorder chemotherapy; metabolism disorder chemotherapy; pediatric pharmacology; pharmacokinetics

Cysteamine therapy of nephropathic cystinosis received new drug approval from the FDA on August 15, 1994. The clinical investigation leading to new drug approval was initiated by Dr. Thoene at the University of Michigan in 1978. At this time the above referenced protocol is maintained to assist those children who cannot tolerate the marketed version which is prepared only in 50 mg and 200 mg capsules.

半胱胺治疗肾病性胱氨酸病获得新药批准 FDA于1994年8月15日 临床研究导致 新药批准是由Thoene博士发起的， 1978年的密歇根州。 此时，上述参考方案是 帮助那些无法忍受市场上销售的 该版本仅以50 mg和200 mg胶囊制备。